Roth Capital Has Positive Forecast for ZVRA Q1 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at Roth Capital lifted their Q1 2025 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note issued to investors on Sunday, February 9th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($0.27) per share for the quarter, up from their prior estimate of ($0.30). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at $0.09 EPS, FY2025 earnings at ($0.17) EPS, FY2026 earnings at $0.82 EPS, FY2027 earnings at $1.53 EPS and FY2028 earnings at $1.97 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. During the same quarter in the previous year, the company posted ($0.40) EPS.

A number of other research analysts also recently issued reports on the company. Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Cantor Fitzgerald upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Zevra Therapeutics has an average rating of “Buy” and an average price target of $21.57.

Zevra Therapeutics Trading Up 3.5 %

NASDAQ:ZVRA opened at $7.99 on Wednesday. The stock’s 50 day moving average price is $8.26 and its 200 day moving average price is $8.03. The company has a market capitalization of $426.51 million, a PE ratio of -4.06 and a beta of 2.00. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76.

Institutional Trading of Zevra Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC lifted its holdings in shares of Zevra Therapeutics by 402.9% in the 4th quarter. Barclays PLC now owns 289,688 shares of the company’s stock valued at $2,416,000 after buying an additional 232,089 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Zevra Therapeutics in the 4th quarter valued at approximately $224,000. Invesco Ltd. lifted its holdings in shares of Zevra Therapeutics by 19.6% in the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company’s stock valued at $153,000 after buying an additional 3,007 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Zevra Therapeutics by 65.4% in the 4th quarter. Wells Fargo & Company MN now owns 29,701 shares of the company’s stock valued at $248,000 after buying an additional 11,744 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Zevra Therapeutics by 13.8% in the 4th quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company’s stock valued at $9,912,000 after buying an additional 144,256 shares during the period. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.